Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs
LD Saravolatz, S Depcinski… - Clinical Infectious …, 2023 - academic.oup.com
At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …
[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during …
LE Wee, AT Tay, C Chiew, BE Young, B Wong… - Clinical Microbiology …, 2023 - Elsevier
Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
G Martin-Blondel, AG Marcelin, C Soulié… - Journal of …, 2022 - journalofinfection.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related coronavirus
disease 2019 (COVID-19) manifests with symptoms ranging from fully asymptomatic to …
disease 2019 (COVID-19) manifests with symptoms ranging from fully asymptomatic to …
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales …
A Evans, C Qi, JO Adebayo, J Underwood, J Coulson… - Journal of Infection, 2023 - Elsevier
Objective To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …
[HTML][HTML] Early clinical experience with molnupiravir for mild to moderate breakthrough COVID-19 among fully vaccinated patients at risk for disease progression
A Vena, L Traman, M Bavastro, A Limongelli… - Vaccines, 2022 - mdpi.com
Information on the efficacy and safety of molnupiravir in daily clinical practice is very scarce.
We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients …
We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients …
[HTML][HTML] Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a …
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
Y Wang, D Zhao, X Chen, X Liu… - Influenza and other …, 2023 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …